Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Transplant Proc ; 42(4): 1146-7, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20534246

RESUMEN

Renal transplant recipients are at increased risk of infectious diseases and subject to cutaneous infections because of the effects of immunosuppressive therapy. Some long-term descriptive follow-up studies confirm that skin infections are common among renal transplant recipients. We report the development of subcutaneous nodules among patients receiving renal transplantations from 1991 to 2009. Transplant recipients were followed by the Nephrology Unit at control visits according to the American Society Nephrology guidelines. Between 1991 to 2009, subcutaneous nodules were identified in 7 out of 774 renal transplant recipients. The male:female ratio was 5:2; median age at renal transplantation was 52 years (range 28-59). Subcutaneous nodules were identified at a median 3 years after transplantation. The 7 patients had the following diagnoses: systemic scedosporiasis (n = 1); Mycobacterium avium complex infection (n = 2) disseminated tuberculosis (n = 2) Sporothrix schenckii infection (n = 1); Trichophyton rubrum infection (n = 1). Four patients died due to sepsis from disseminated infection. Subcutaneous nodules may reflect a systemic infectious pathology. In some cases, the investigation of cutaneous lesions is important to reach a definitive diagnosis for possible future disseminated infections.


Asunto(s)
Infecciones/epidemiología , Trasplante de Riñón/efectos adversos , Enfermedades de la Piel/epidemiología , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/mortalidad , Femenino , Humanos , Infecciones/mortalidad , Masculino , Persona de Mediana Edad , Micetoma/microbiología , Estudios Retrospectivos , Scedosporium/patogenicidad , Caracteres Sexuales , Sporothrix , Esporotricosis/diagnóstico , Tuberculosis Pulmonar/epidemiología
2.
Clin Microbiol Infect ; 16(8): 1130-4, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19832722

RESUMEN

The treatment of multidrug-resistant tuberculosis (TB) requires the use, for long periods, of drugs liable to cause significant side effects. In the case of misdiagnosis of multidrug-resistant TB, the patient is exposed to toxic substances without any benefit. In low-income countries, where the microbiological diagnosis of TB relies on microscopy only, the misdiagnosis of multidrug-resistant TB is very frequent in patients persistently smear-positive despite anti-TB treatment, with the possibility of an infection due to non-tuberculous mycobacteria (NTM) being neglected. The isolation of a mycobacterium from the sputum of a Somali patient apparently confirmed the previous diagnosis of cavitary pulmonary disease. Preliminary investigations led, at first, to the strain being identified as multidrug-resistant Mycobacterium tuberculosis, with findings fully in agreement with the patient's history, which was characterized by repeated interruptions of anti-TB treatment. Thorough phenotypic and genotypic analyses led subsequently to the recognition that the strain was a previously unreported non-tuberculous mycobacterium. The patient, who was unresponsive to the anti-TB treatment, dramatically improved once a drug combination active against NTM was used. A major objective of this article is to alert the medical community to the risk, present also in settings in which sophisticated diagnostic techniques are used, that a cavitary infection due to NTM, and consequently not responding to the anti-TB standard regimen, will be mistaken for multidrug-resistant TB.


Asunto(s)
Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Micobacterias no Tuberculosas/efectos de los fármacos , Micobacterias no Tuberculosas/aislamiento & purificación , Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico , Tuberculosis Pulmonar/diagnóstico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cromatografía Líquida de Alta Presión , Análisis por Conglomerados , ADN Bacteriano/química , ADN Bacteriano/genética , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Datos de Secuencia Molecular , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Infecciones por Mycobacterium no Tuberculosas/microbiología , Ácidos Micólicos/análisis , Micobacterias no Tuberculosas/clasificación , Micobacterias no Tuberculosas/genética , Filogenia , Radiografía Torácica , Análisis de Secuencia de ADN , Somalia , Tomografía Computarizada por Rayos X , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/microbiología
3.
Transplant Proc ; 39(6): 2033-5, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17692684

RESUMEN

Scedosporium apiospermum, the asexual form of Pseudallescheria boydii, is a ubiquitous fungus that represents an unfrequent complication of immune suppression. It accounts for 20% of all non-Aspergillus mold infections in organ transplant recipients. The infection can be localized or disseminated in multiple organs, including lungs, brain, joints, tendons, and skin, and is difficult to treat, due to resistance of S apiospermum to amphotericin B and other antifungal agents. The mortality rate is about 50%. To our knowledge, there are no prospective studies or registries of transplant recipients to guide diagnosis and there are no evidence-based recommendations for the optimal management of this infection. We report a case of S apiospermum infection in a woman with renal transplantation. The first occurrence of infection was a solitary nodule on the forearm, which was surgically excised. Two following relapses were disseminated to the knee, the Achilles tendon, and the skin of the left leg. The infection was successfully treated with voriconazole, but due to the severe iatrogenic immune suppression, a strong reduction in immunosuppressant drugs was needed.


Asunto(s)
Antifúngicos/uso terapéutico , Trasplante de Riñón/efectos adversos , Micetoma/tratamiento farmacológico , Micetoma/etiología , Complicaciones Posoperatorias/microbiología , Pirimidinas/uso terapéutico , Scedosporium , Triazoles/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Micetoma/diagnóstico por imagen , Complicaciones Posoperatorias/diagnóstico por imagen , Complicaciones Posoperatorias/tratamiento farmacológico , Ultrasonografía , Voriconazol
4.
Cancer Res ; 56(17): 3883-5, 1996 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-8752151

RESUMEN

Failure of tamoxifen treatment for unresectable hepatocellular carcinomas (HCCs) might be caused by variant estrogen receptors (ERs) in some of these tumors. We therefore planned a study in which antihormonal therapy was done with 80 mg/day tamoxifen or 160 mg/day megestrol according to the presence of wild-type or exon 5-deleted variant ER transcripts. Growth rate (evaluated by MRI) of HCCs characterized by variant ER transcripts was 4 times more rapid than that of HCCs with wild-type ERs. Tumor volume in all patients with wild-type ERs was halved after 9 months of tamoxifen treatment, whereas megestrol in patients with variant ERs only slowed down tumor growth. Choosing antihormonal treatment according to the presence of wild-type or variant ERs in the tumor definitely improves the response rate to tamoxifen; in patients with tumors bearing variant ERs, megestrol causes only a temporary inhibition of tumor growth.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/ultraestructura , Antagonistas de Estrógenos/uso terapéutico , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/ultraestructura , Megestrol/uso terapéutico , Receptores de Estrógenos/fisiología , Tamoxifeno/uso terapéutico , Adulto , Anciano , Carcinoma Hepatocelular/metabolismo , División Celular/efectos de los fármacos , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Hepáticas/metabolismo , Masculino , Persona de Mediana Edad , Proyectos Piloto , Receptores de Estrógenos/clasificación , Receptores de Estrógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...